Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2005 2
2006 1
2007 1
2008 2
2009 2
2010 7
2011 10
2012 11
2013 14
2014 22
2015 7
2016 11
2017 12
2018 5
2019 7
2020 10
2021 11
2022 36
2023 17
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25081901

175 results

Results by year

Filters applied: . Clear all
Page 1
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. Chung CH, et al. Ann Oncol. 2014 Nov;25(11):2230-2236. doi: 10.1093/annonc/mdu367. Epub 2014 Jul 31. Ann Oncol. 2014. PMID: 25081901 Free PMC article. Clinical Trial.
The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. Weidhaas JB, et al. JAMA Oncol. 2017 Apr 1;3(4):483-491. doi: 10.1001/jamaoncol.2016.5478. JAMA Oncol. 2017. PMID: 28006059 Free PMC article. Clinical Trial.
Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
Vermorken JB, Psyrri A, Mesía R, Peyrade F, Beier F, de Blas B, Celik I, Licitra L. Vermorken JB, et al. Ann Oncol. 2014 Apr;25(4):801-807. doi: 10.1093/annonc/mdt574. Epub 2014 Feb 26. Ann Oncol. 2014. PMID: 24577117 Free PMC article.
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O, Vacher S, Lecerf C, Jeannot E, Klijanienko J, Berger F, Hoffmann C, Calugaru V, Badois N, Chilles A, Lesnik M, Krhili S, Bieche I, Le Tourneau C, Kamal M. Leblanc O, et al. Cancer Biol Med. 2020 Feb 15;17(1):208-217. doi: 10.20892/j.issn.2095-3941.2019.0153. Cancer Biol Med. 2020. PMID: 32296588 Free PMC article.
No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.
Prigge ES, Urban K, Stiegler S, Müller M, Kloor M, Mai S, Ottstadt M, Lohr F, Wenz F, Wagner S, Wittekindt C, Klussmann JP, Hampl M, von Knebel Doeberitz M, Reuschenbach M. Prigge ES, et al. Hum Pathol. 2014 Nov;45(11):2347-54. doi: 10.1016/j.humpath.2014.08.001. Epub 2014 Aug 23. Hum Pathol. 2014. PMID: 25257576
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti E, Petrillo A, Sandomenico F, Maiolino P, D'Aniello R, Botti G, De Cecio R, Losito NS, Scala S, Trotta A, Zotti AI, Bruzzese F, Daponte A, Calogero E, Montano M, Pontone M, De Feo G, Perri F, Budillon A. Caponigro F, et al. BMC Cancer. 2016 Nov 25;16(1):918. doi: 10.1186/s12885-016-2957-y. BMC Cancer. 2016. PMID: 27884140 Free PMC article. Clinical Trial.
A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S. Saridaki Z, et al. Clin Cancer Res. 2014 Sep 1;20(17):4499-4510. doi: 10.1158/1078-0432.CCR-14-0348. Clin Cancer Res. 2014. PMID: 25183481 Free PMC article.
175 results